Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regeneration
ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) — Acuitive Technologies(R) commercializes Citregraft(TM), with its first use in a surgical case, performed on November 4th, 2025. Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their […]